Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $1.165 million, down from $1.958 million year-over-year.

Revenue Breakdown: Decrease attributed to lower research and development revenue ($183,000) and license/milestone revenue ($1.425 million), partially offset by an increase in grant revenue ($815,000).

Operating Loss: Increased to $1.925 million from $203,000 year-over-year.

Net Loss: Expanded to $1.976 million ($0.06 per share) compared to $203,000 ($0.01 per share) in the prior year.

Cash Position: As of September 30, 2025, cash and equivalents totaled approximately $10.4 million, up from $9.3 million at the end of 2024.

2Strategic Updates and Business Highlights

Rebranding: Transitioned to Dyadic Applied Biosolutions, enhancing focus on commercial biotechnology.

First Commercial Sale: Achieved first bulk sale of a Dyadic protein, marking a significant milestone in commercialization.

Product Development: Advancements in recombinant human albumin, fibroblast growth factor (FGF), transferrin, and DNase I, with several products nearing commercial launch.

Partnerships: Collaborated with Intralink for market penetration in Asia, targeting growth in cell culture media and molecular biology reagents.

CRISPR Technology: Secured a license with ERS Genomics to enhance genetic engineering capabilities, expected to improve product development and optimization.

3Forward Guidance and Outlook

Revenue Growth: Anticipate growth in product revenue from life sciences and food nutrition markets in 2025, with a focus on launching cell culture media and molecular biology products.

Market Expansion: Plans to leverage partnerships to penetrate key global markets, particularly in Asia, with expectations of increased customer engagement.

Operational Focus: Maintain operating expenses in line with previous years while scaling product offerings.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Notable decrease in total revenue and increased operational losses raise concerns about financial sustainability in the short term.

Market Competition: The biotechnology sector is highly competitive, and Dyadic must effectively differentiate its products to capture market share.

Regulatory Hurdles: Potential challenges in obtaining regulatory approvals for new products, particularly in food nutrition and biopharmaceutical sectors, could delay commercialization efforts.

5Notable Q&A Insights

CRISPR Agreement: The CRISPR license is expected to provide a competitive advantage by enhancing product development capabilities, particularly in food and nutrition sectors.

DNase I Market Potential: The market for DNase I is estimated at $250 million for recombinant products, with expectations for rapid scaling through OEM agreements.

Asian Market Strategy: Focus on targeting cell and gene therapy manufacturers in Asia, leveraging local partnerships to navigate market dynamics and reduce tariff implications.

Infant Nutrition Products: Dyadic aims to mimic human breast milk with its recombinant proteins, addressing sustainability and quality concerns in infant nutrition. Overall, Dyadic International, Inc. is navigating a transformative phase with a focus on commercialization and product development, despite facing financial challenges and competitive pressures. The company is optimistic about future growth driven by strategic partnerships and product launches.